VZ
| Title | Published in | Access level | OA Policy | Year | Views | Downloads | |
|---|---|---|---|---|---|---|---|
| UHPLC-MS-based HDAC Assay Applied to Bio-guided Microfractionation of Fungal Extracts | Phytochemical analysis |  | 2017 | 515 | 3 | ||
| Synthesis of an Uncharged Tetra-cyclopeptide Acting as a Transmembrane Carrier: Enhanced Cellular and Nuclear Uptake | Organic letters | | 2017 | 474 | 0 | ||
| Hydroxyl Ketone-Based Histone Deacetylase Inhibitors To Gain Insight into Class I HDAC Selectivity versus That of HDAC6 | ACS Omega |  | 2017 | 399 | 347 | ||
| Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS | Journal of Visualized Experiments | | 2017 | 382 | 247 | ||
| Cell-based multi-substrate assay coupled to UHPLC-ESI-MS/MS for a quick identification of class-specific HDAC inhibitors | Journal of enzyme inhibition and medicinal chemistry | | 2016 | 461 | 1 | ||
| HDAC inhibitors from natural and synthetic libraries: towards the development of biochemical probes | | 2016 | 901 | 532 | |||
| Synthesis of a selective HDAC6 inhibitor active in neuroblasts | Bioorganic & medicinal chemistry letters | | 2016 | 394 | 0 | ||
| Cross metathesis with hydroxamate and benzamide BOC-protected alkenes to access HDAC inhibitors and their biological evaluation highlighted intrinsic activity of BOC-protected dihydroxamates | Bioorganic & medicinal chemistry letters | | 2016 | 525 | 0 | ||
| Biphenyl-4-yl-acrylohydroxamic acids: Identification of a novel indolyl-substituted HDAC inhibitor with antitumor activity | European journal of medicinal chemistry | | 2016 | 459 | 1 | ||
| Superacid and thiol-ene reactions for access to psammaplin analogues with HDAC inhibition activities | Tetrahedron | | 2014 | 477 | 0 | ||
| Aurones as histone deacetylase inhibitors: identification of key features | Bioorganic & medicinal chemistry letters | | 2014 | 530 | 2 | ||
| Cancer chemopreventive diterpenes from Salvia corrugata | Phytochemistry | | 2013 | 723 | 4 | ||
| HDAC6 as a target for neurodegenerative diseases: what makes it different from the other HDACs? | Molecular neurodegeneration | | 2013 | 682 | 437 |
